Switching to biosimilars in the treatment of rheumatic diseases

References

• European Medicinal Agency: EMEA/CHMP/BMWP/42832/2005 Rev1. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Edited at 18 Dec 2014.
   Google Scholar
• Sokka T, Kautiainen H, Pincus T, et al. Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. Ann Rheum Dis. 2009 68:1666–1672.
   PubMedGoogle Scholar
• Putrik P, Ramiro S, Keszei AP, et al. Lower education and living in countries with lower wealth are associated with higher disease activity in rheumatoid arthritis: results from the multinational COMORA study. Ann Rheum Dis. 2016;75:540–546.
   PubMedGoogle Scholar
• Schulze-Koops H. Skapenko A. Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm. Rheumatology (Oxford). 2017;56(suppl_4):iv30–iv48.
   Web of Science ®Google Scholar
• Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76:960–977.
   PubMed Web of Science ®Google Scholar
• GaBi: Biosimilar approved in Europe. updated. 2 Feb 2018. [cited 2018 Jun 08]. Available from http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe
   Google Scholar
• Braun J. Kudrin A. Switching to biosimilar infliximab (CT-P13): evidence of clinical safety, effectiveness and impact on public health. Biologicals. 2016;44:257–266.
   PubMed Web of Science ®Google Scholar
• Yoo DH. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis. Expert Rev Clin Immunol. 2014;10:981–983.
   PubMed Web of Science ®Google Scholar
• Toussirot E. Marotte H. Switching from originator biological agents to biosimilars: what is the evidence and what are the issues?. RMD Open. 2017;3:e000492.
   PubMed Web of Science ®Google Scholar
• Kay J, Schoels MM, Dorner T, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018;77:165–174.
   PubMed Web of Science ®Google Scholar
• Uhlig T, Gl G. Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons. Rheumatology (Oxford). 2017;56:iv49–iv62.
   PubMed Web of Science ®Google Scholar
• Cantini F, Benucci M. Switching from the bio-originators to biosimilar: is it premature to recommend this procedure? Ann Rheum Dis. 2017 Dec 29. pii: annrheumdis-2017–212820. doi:10.1136/annrheumdis-2017-212820. Epub ahead of print.
   PubMedGoogle Scholar
• Cantini F, Niccoli L, Nannini C, et al. Rapid loss of efficacy of biosimilar infliximab in three patients with Behcet’s disease after switching from infliximab originator. Eur J Rheumatol. 2017;4:288–290.
   PubMed Web of Science ®Google Scholar
• Fleischmann R. Therapy: biosimilars in rheumatology - why, how and when in 2017. Nat Rev Rheumatol. 2017;13:701–703.
   PubMed Web of Science ®Google Scholar
• US Food Drug Administration. Considerations in demonstrating interchangeability with a reference product-guidance for industry. [cited 2018 Jun 08]. Available from: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM537135.pdf. 2017.
   Google Scholar
• Moorkens E, Vulto AG, Huys I, et al. Policies for biosimilar uptake in Europe: an overview. PLoS One. 2017;12:e0190147.
   PubMed Web of Science ®Google Scholar
• Kurki P. Ekman N. Biosimilar regulation in the EU. Expert Rev Clin Pharmacol. 2015;8:649–659.
   PubMed Web of Science ®Google Scholar
• Kurki P, van Aerts L, Wolff-Holz E, et al. Interchangeability of Biosimilars: a European Perspective. BioDrugs. 2017;31:83–91.
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Thaci D, Gerdes S, et al. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2017;176:928–938.
   PubMed Web of Science ®Google Scholar
• US Food Drug Administration. 17 Jan 2017. Considerations in Demonstrating Interchangeability with a Reference Product Guidance for Industry. draft guidance. [cited 2018 Jun 08]. Available from https://www.federalregister.gov/documents/2017/01/18/2017-01042/considerations-in-demonstrating-interchangeability-with-a-reference-product-draft-guidance-for
   Google Scholar
• Moots R, Azevedo V, Coindreau JL, et al. Switching between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: considerations for the Clinician. Curr Rheumatol Rep. 2017;19:37.
   PubMed Web of Science ®Google Scholar
• Zink A, Strangfeld A, Schneider M, et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum. 2006;54:3399–3407.
   PubMed Web of Science ®Google Scholar
• Aaltonen KJ, Ylikyla S, Tuulikki Joensuu J, et al. Efficacy and effectiveness of tumour necrosis factor inhibitors in the treatment of rheumatoid arthritis in randomized controlled trials and routine clinical practice. Rheumatology (Oxford). 2017;56:725–735.
   PubMed Web of Science ®Google Scholar
• Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2017;76:355–363.
   PubMed Web of Science ®Google Scholar
• Park W, Yoo DH, Miranda P, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis. 2017;76:346–354.
   PubMed Web of Science ®Google Scholar
• Emery P, Vencovsky J, Sylwestrzak A, et al. Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4. Ann Rheum Dis. 2017 Aug 9. DOI: 10.1136/annrheumdis-2017-211591. pii: annrheumdis-2017211591 Epub ahead of print.
   Web of Science ®Google Scholar
• Smolen JS, Choe JY, Prodanovic N, et al. Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study. Ann Rheum Dis. 2018;77:234–240.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Burmester GR. Olech E. Biosimilars: rationale and current regulatory landscape. Ann Rheum Dis. 2016;45:S1–10.
   Google Scholar
• Reinisch W. Smolen J. Biosimilar safety factors in clinical practice. Semin Arthritis Rheum. 2015;44:S9–15.
   PubMed Web of Science ®Google Scholar
• Kim JS, Kim SH, Kwon B, et al. Comparison of immunogenicity test methods used in clinical studies of infliximab and its biosimilar (CT-P13). Expert Rev Clin Immunol. 2015;11(Suppl 1):S33–41.
   PubMedGoogle Scholar
• Pineda C, Castaneda Hernandez G, Jacobs IA, et al. Assessing the Immunogenicity of Biopharmaceuticals. BioDrugs. 2016;30:195–206.
   PubMed Web of Science ®Google Scholar
• Braun J. Kay J. The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis. Expert Opin Drug Saf. 2017;16:289–302.
   PubMed Web of Science ®Google Scholar
• Ruiz-Arguello MB, Maguregui A, Del R, et al. Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars. Ann Rheum Dis. 2016;75:1693–1696.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Jahnsen J, Schreiber S, et al. Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): an Analysis Using Immunoassays Tagged with Both Agents. BioDrugs. 2017;31:223–237.
   PubMed Web of Science ®Google Scholar
• Yoo DH. Comparative effectiveness of the biosimilar CT-P13. J Comp Eff Res. 2017;6:693–712.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Yamanaka H, Takeuchi T, et al. Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab. Mod Rheumatol. 2017 Mar;27(2):237–245.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Choe JY, Prodanovic N, et al. Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results. Rheumatology (Oxford). 2017(56):1771–1779
   Google Scholar
• Cohen SB, Alten R, Kameda H, et al. A Randomized, Double-Blind Study Comparing PF-06438179/GP1111, a Potential Infliximab Biosimilar, and Infliximab, Both in Combination with MTX, As Treatment for Patients with Moderate to Severe Active RA Who Have Had an Inadequate Response to MTX Therapy. Arthritis Rheumatol. 2017;69: http://acrabstracts.org/abstract/.
   Web of Science ®Google Scholar
• Emery P, Vencovsky J, Sylwestrzak A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017;76:51–57.
   PubMed Web of Science ®Google Scholar
• Emery P, Vencovsky J, Sylwestrzak A, et al. 52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis. Rheumatology (Oxford). 2017;56:2093–2101.
   PubMed Web of Science ®Google Scholar
• Gerdes S, Thaçi D, Griffiths CEM, et al. Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patientswith chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study. J Europ Aca Dermatol Venereol. 2018 Mar;32(3):420–427. DOI:10.1111/jdv.14605.
   PubMed Web of Science ®Google Scholar
• Papp K, Bachelez H, Costanzo A, et al. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study. J Am Acad Dermatol. 2017;76:1093–1102.
   PubMed Web of Science ®Google Scholar
• Papp K, Bachelez H, Costanzo A, et al. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2017;177:1562–1574.
   PubMed Web of Science ®Google Scholar
• Cohen S, Genovese MC, Choy E, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis. 2017;76:1679–1687.
   PubMedGoogle Scholar
• Cohen SB, Alonso-Ruiz A, Klimiuk PA, et al. Biosimilar candidate BI695501 and adalimumab reference product have similar efficacy and safety in patients with moderate to severely active rheumatoid arthritis: 1 year result from a phase III study. Arthritis Rheumatol. 2017;69. Available form: http://acrabstract.org/abstract
   Web of Science ®Google Scholar
• Weinblatt ME, Baranauskaite A, Dokoupilova E, et al. Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: 52-Week Phase 3 Randomized Study Results. Arthritis Rheumatol. 2018 Jun;70(6):832–840.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Glover J, Matsunaga N, et al. Efficacy, Safety and Immunogenicity in Randomized, Double-Blind (DB) and Open-Label Extension (OLE) Studies Comparing FKB327, an Adalimumab Biosimilar, with the Adalimumab Reference Product (Humira®; RP) in Patients (pts) with Active Rheumatoid Arthritis (RA). Arthritis Rheumatol. 2017;69. Available form: http://acrabstracts.org/abstract/
   Web of Science ®Google Scholar
• Blauvelt A, Lacour JP, Fowler J, et al. Long-Term Efficacy, Safety and Immunogenicity Results from a Randomized, Double-Blind, Phase III Confirmatory Efficacy and Safety Study Comparing GP2017, a Proposed Biosimilar, with Reference Adalimumab. Arthritis Rheumatol. 2017;69. Available form: http://acrabstracts.org/abstract/
   Web of Science ®Google Scholar
• Hodge J, Tang H, O'Connor P, et al. Switching from Adalimumab to Chs-1420: A Randomized, Double-Blind Global Clinical Trial in Patients with Psoriasis and Psoriatic Arthritis. Arthritis Rheumatol. 2017;69. Available form: http://acrabstracts.org/abstract/
   Web of Science ®Google Scholar
• Park W, Suh CH, Shim SC, et al. Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis. BioDrugs. 2017;31:369–377.
   PubMed Web of Science ®Google Scholar
• Shim SC, Kasay AB, El-Khouri EC, et al. Efficacy and Safety of Rituximab Biosimilar, CT-P10, after a Single Switch from Innovator Rituximabs in Patients with Rheumatoid Arthritis: results from Phase 3 Randomized Controlled Trial over 72 Weeks. Arthritis Rheumatol. 2017;69: http://acrabstracts.org/abstract/.
   Web of Science ®Google Scholar
• Tony HP, Schulze-Koops H, Krüger K, et al. Comparison of Switching from the Originator Rituximab to the Biosimilar Rituximab GP2013 or Re‑Treatment with the Originator Rituximab in Patients with Active Rheumatoid Arthritis: safety and Immunogenicity Results from a Multicenter, Randomized, Double-Blind Study. Arthritis Rheumatology. 2017;69: http://acrabstracts.org/abstract/.
   Web of Science ®Google Scholar
• Nasonov E, Mazurov V, Plaksina T, et al. Interchangeability of Innovator Rituximab and Its Biosimilar: results from International Controlled Comparative 1-Year Study in Patients with Active Rheumatoid Arthritis. Arthritis Rheumatol. 2016;68. Available form: http://acrabstracts.org/abstract/
   Web of Science ®Google Scholar
• Jorgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389:2304–2316.
   PubMed Web of Science ®Google Scholar
• Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677–1683.
   Google Scholar
• GaBi online: Position paper Finland. Posted 29 May 2015. [cited 2018 Jun 08]. Avaiable at http://www.gabionline.net/Policies-Legislation/Finnish-drug-regulator-recommends-interchangeability-of-biosimilars
   Google Scholar
• Glintborg B, Sorensen IJ, Loft AG, et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis. 2017;76:1426–1431.
   PubMed Web of Science ®Google Scholar
• Abdalla A, Byrne N, Conway R, et al. Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product. Open Access Rheumatol. 2017;9:29–35.
   PubMed Web of Science ®Google Scholar
• Vergara-Dangond C, Saez Bello M, Climente Marti M, et al. Effectiveness and Safety of Switching from Innovator Infliximab to Biosimilar CT-P13 in Inflammatory Rheumatic Diseases: a Real-World Case Study. Drugs R D. 2017;17:481–485.
   PubMed Web of Science ®Google Scholar
• Avouac J, Molto A, Abitbol V, et al. Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: the experience of Cochin University Hospital, Paris, France. Semin Arthritis Rheum. 2018;47:741–748.
   PubMed Web of Science ®Google Scholar
• Lim KJ, Lee SJ, Kim S, et al. Comparable Immune Function Inhibition by the Infliximab Biosimilar CT-P13: implications for Treatment of Inflammatory Bowel Disease. J Crohns Colitis. 2017;11:593–602.
   PubMed Web of Science ®Google Scholar
• Scherlinger M, Germain V, Labadie C, et al. Switching from originator infliximab to biosimilar CT-P13 in real-life: the weight of patient acceptance. Joint Bone Spine. 2017 Nov 14. DOI: 10.1016/j.jbspin.2017.10.003. pii: S1297–319X(17)30189–6 Epub ahead of print.
   Google Scholar
• Tweehuysen L, van den Bemt BJF, van Ingen IL, et al. Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab. Arthritis Rheumatol. 2018;70:60–68.
   PubMed Web of Science ®Google Scholar
• Benucci M, Gobbi FL, Bandinelli F, et al. Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study. Immunol Res. 2017 Feb;65(1):419–422.
   PubMed Web of Science ®Google Scholar
• Kim DW, Kwon SR, Lee EY, et al. Effectiveness and Safety of CT-P13 in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Plaque Psoriasis: observational Study in Republic of Korea. Arthritis Rheumatol. 2017;69: http://acrabstracts.org/abstract/.
   Web of Science ®Google Scholar
• Glintborg B, Sørensen JJ, Loft AG, et al. Clinical outcomes from a nationwide non-medical switch from originator to biosimilar etanercept in patients with inflammatory arthritis after 5 months follow up results from the DANBIO registry. Ann Rheum Dis. 2017;72. Avaiable at. DOI:10.1136/annrheumdis-2017-eular.1703.
   Google Scholar
• Glintborg B, Omerovic E, Danebod K, et al. One-Year Clinical Outcomes in 1623 Patients with Inflammatory Arthritis Who Switched from Originator to Biosimilar Etanercept – an Observational Study from the Danish Danbio Registry. Arthritis Rheumatol. 2017;69: http://acrabstracts.org/abstract/.
   Web of Science ®Google Scholar
• Tweehuysen L, Huiskes VJB, van den Bemt BJF, et al. Open Label Transitioning from Originator Etanercept to Biosimilar SB4 Compared to Continuing Treatment with Originator Etanercept in a Historical Cohort in Rheumatic Diseases in Daily Practice. Arthritis Rheumatol. 2017;67(S10). Available from: http://acrabstracts.org/abstract/open-label-transitioning-fromoriginator-etanercept-to-biosimilar-sb4-compared-to-continuing-treatment-with-originator-etanercept-in-a-historicalcohort-in-rheumatic-diseases-in-daily-practice.
   Google Scholar
• Sigurdardottir V, Husmark T, Svärd A. Switching from reference product etanercept to the biosimilar sb4 in a real-life setting: follow-up of 147 patients. Ann Rheum Dis. 2017;72(Suppl 2):835.
   Google Scholar
• Holroyd C, Wallis D, Bennett S, et al. Switching from bio-original etanercept to biosimilar etanercept sb4: patient acceptability and outcomes in the real world. Ann Rheum Dis. 2017;76(Suppl 2):1180.
   Web of Science ®Google Scholar
• Presberg Y, Foltz V, L’Amour C, et al. Interchangeability from infliximab originator to infliximab biosimilar: efficacy and safety in a prospective observational study on 89 patients. Ann Rheum Dis. 2017;76(Suppl 2):450.
   Web of Science ®Google Scholar
• Akrout W, Bosycot A, Levet-Labry R, et al. Transition from ongoing infliximab reference product to its biosimilar: can we talk about a failure? Ann Rheum Dis. 2017;76(Suppl 2):1301.
   Web of Science ®Google Scholar
• Holroyd C, Parker L, Bennett S, et al. Switching to biosimilar infliximab: real world data from the Southampton biologic therapies review service. Rheumatology (Oxford). 2016;55(Suppl 1):i60–61.
   Google Scholar
• Colloca L. Finniss D. Nocebo effects, patient-clinician communication, and therapeutic outcomes. JAMA. 2012;307:567–568.
   PubMed Web of Science ®Google Scholar
• Waller J, Sullivan E, Piercy J, et al. Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany. Patient Prefer Adherence. 2017;11:519–530.
   Google Scholar